Progression-free survival with darolutamide and docetaxel vs. androgen receptor pathway inhibitors vs. docetaxel in metastatic hormone-sensitive prostate cancer: A real-world multicenter retrospective
11 hours ago
- #real-world data
- #treatment outcomes
- #prostate cancer
- Study compares progression-free survival (PFS) in metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with docetaxel + ADT, ARPI + ADT, or darolutamide + docetaxel + ADT.
- Real-world multicenter retrospective analysis of 346 men with mHSPC from 13 centers.
- Primary endpoint was PFS; secondary endpoints included adverse events.
- Inverse probability of treatment weighting (IPTW) used to address baseline imbalances.
- No significant differences in PFS observed after IPTW adjustment between treatment groups.
- Grade ≥3 adverse events varied: 36.2% (docetaxel + ADT), 10.9% (ARPI + ADT), 31.8% (triplet therapy).
- Triplet therapy did not show significant PFS improvement over ARPI + ADT or docetaxel + ADT.
- Findings limited by sample size and follow-up; further prospective studies recommended.